Skip to main content
. Author manuscript; available in PMC: 2014 May 15.
Published in final edited form as: Int J Cancer. 2012 Nov 23;132(10):10.1002/ijc.27919. doi: 10.1002/ijc.27919

Figure 3.

Figure 3

Effect of NZ-1-(scdsFv)-PE38KDEL on D2159MG and D283MED subcutaneous tumors in athymic nude mice. Female athymic nude mice (≈20 g; 4–6 weeks) bearing D2159MG tumors (a) or D283MED tumors (b) were randomized into three groups, 0.2% PBS-HSA (■), P588-(scFv)-PE38KDEL (▲), and NZ-1-(scdsFv)-PE38KDEL (●). Once the tumors reached an average volume of 150–300 mm3, the mice were treated by i.t. injections every other day with a total of three 0.3-mg/kg doses of P588-(scFv)-PE38KDEL or NZ-1-(scdsFv)-PE38KDEL diluted in 0.2% PBS-HSA or with 0.2% PBS-HSA alone.